1-4 of 4
Catherine Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor

Grzegorz S. Nowakowski, Anna Paulina Dabrowska-Iwanicka, Christian Grommes, Han W. Tun, Christopher D' Angelo, Adolfo De la Fuente Burguera, Etai Levi, Radhakrishnan Ramchandren, Andrés José María Ferreri, Gaurav S Choudhary, Wanying Zhao, Dora Ferrari, Meaghan Fowle, Maureen Lane, Catherine Wang, Michal Taszner
Journal: Blood
Blood (2024) 144 (Supplement 1): 6020.
https://doi.org/10.1182/blood-2024-208359
Published: 2024
Journal Articles

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Christian Grommes, Han Tun, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Wanying Zhao, Maureen Lane, Catherine Wang, Reinhard von Roemeling, Iris Isufi, Lori A. Leslie, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4497.
https://doi.org/10.1182/blood-2023-189746
Published: 2023
Journal Articles

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

Christian Grommes, Grzegorz S. Nowakowski, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Meaghan Fowle, Maureen Lane, Catherine Wang, Antonio Omuro, Lori A. Leslie, Carole Soussain, Anna Paulina Dabrowska-Iwanicka, Andrés José María Ferreri, Han Tun
Journal: Blood
Blood (2023) 142 (Supplement 1): 3143.
https://doi.org/10.1182/blood-2023-190391
Published: 2023
Journal Articles

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Adam D. Cohen, MD, Rakesh Popat, Suzanne Trudel, MD, Paul G Richardson, MD, Ed N. Libby, III, MD, Nikoletta Lendvai, MDPhD, Larry D. Anderson, Jr., MD PhD, Heather J. Sutherland, MD PhD, Stephen DeWall, Catherine E Ellis, Zangdong He, Jolly Mazumdar, Catherine Wang, Joanna B. Opalinska, MD PhD, Peter M. Voorhees, MD
Journal: Blood
Blood (2016) 128 (22): 1148.
https://doi.org/10.1182/blood.V128.22.1148.1148
Published: 2016